Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ. Di Bisceglie AM, et al. Among authors: kieffer t. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):761-73. doi: 10.1097/MEG.0000000000000084. Eur J Gastroenterol Hepatol. 2014. PMID: 24901821 Clinical Trial.
Telaprevir for previously untreated chronic hepatitis C virus infection.
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Jacobson IM, et al. N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912. N Engl J Med. 2011. PMID: 21696307 Free article. Clinical Trial.
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. Kieffer TL, et al. PLoS One. 2012;7(4):e34372. doi: 10.1371/journal.pone.0034372. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511937 Free PMC article.
Resistance to hepatitis C virus protease inhibitors.
Kieffer TL, George S. Kieffer TL, et al. Curr Opin Virol. 2014 Oct;8:16-21. doi: 10.1016/j.coviro.2014.04.008. Epub 2014 May 21. Curr Opin Virol. 2014. PMID: 24852142 Review.
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Sullivan JC, et al. Clin Infect Dis. 2013 Jul;57(2):221-9. doi: 10.1093/cid/cit226. Epub 2013 Apr 10. Clin Infect Dis. 2013. PMID: 23575197 Clinical Trial.
282 results